Last updated: February 20, 2026
Case Overview
Sun Pharmaceutical Industries Limited filed a patent infringement suit against Novartis Pharmaceuticals Corp. in the District Court for the District of New Jersey. The case, docket number 2:19-cv-00276, centers on the alleged infringement of patents related to a specific pharmaceutical formulation.
Filing Date and Court
- Filing Date: February 8, 2019
- Court: District of New Jersey
Parties
- Plaintiff: Sun Pharmaceutical Industries Limited, an Indian multinational pharmaceutical company.
- Defendant: Novartis Pharmaceuticals Corp., a subsidiary of Novartis AG, based in Switzerland.
Patent-in-Suit
The patent asserted is U.S. Patent No. 9,695,663, titled "Pharmaceutical Composition," which covers a sustained-release formulation of a specific active pharmaceutical ingredient (API) used for treatment of certain medical conditions.
Core Allegations
Sun Pharma claims Novartis's product infringes the '663 patent by manufacturing and marketing a drug formulation that falls within the patent claims. The patent covers specific composition parameters, including API concentration, excipient ratios, and release profiles.
Patent Details
| Patent Number |
Issue Date |
Expiration Date |
Status |
Claims |
| US 9,695,663 |
April 25, 2017 |
April 25, 2034 |
Valid |
Claims cover sustained-release formulations with specific API and excipient ratios for certain therapeutic indications. |
Legal Proceedings
Complaint Claims
- Infringement: Novartis's product infringes the '663 patent by its manufacturing, sale, and distribution.
- Unenforceability: Sun Pharma alleges the patent is valid, enforceable, and infringed.
Defense Strategies (as observed)
While the case is ongoing, typical defenses are expected to include:
- Patent invalidity arguments based on prior art.
- Non-infringement claims by asserting differences in formulation parameters.
- Patent unenforceability due to alleged inequitable conduct during patent prosecution.
Key Motions and Events
- Pre-trial motions: Both parties filed motions to dismiss and motions for summary judgment.
- Markman hearing: The court issued a claim construction order, defining critical terms in the patent claims.
- Discovery phase: Ongoing, with technical disclosures and product samples exchanged.
Litigation Timeline Highlights
| Date |
Event |
| February 8, 2019 |
Complaint filed |
| July 15, 2019 |
Patent infringement claim asserted |
| March 10, 2020 |
Court's claim construction order issued |
| September 2020 |
Motions for summary judgment filed |
| December 2020 |
Court denied motions, scheduled trial date |
| June 2021 |
Trial date scheduled, case remains active |
Industry and Patent Litigation Context
This case reflects ongoing patent disputes in the pharmaceutical industry, particularly under Hatch-Waxman Act provisions for biosimilars and branded drug formulations.
It underscores the importance of patent claim drafting, validity defenses based on prior art, and the complexities of infringement analysis for formulations.
Implications & Strategic Considerations
- For patent holders: The case reinforces the value of detailed, specific claims and comprehensive prosecution strategies.
- For generics: Demonstrates the potential challenges in asserting invalidity defenses early in litigation.
- Market Impact: Prolonged litigation can delay generic entry, influencing pricing and availability.
Key Takeaways
- The case exemplifies typical patent infringement litigation involving pharmaceutical formulations.
- The outcome depends heavily on claim construction and the validity assessment of the asserted patent.
- Both parties actively engage in motions challenging validity and scope prior to trial.
- Patent validity and enforceability remain central, with prior art and prosecution history key factors.
Frequently Asked Questions
Q1: When was the patent in suit granted?
A: April 25, 2017.
Q2: What is the legal basis for Sun Pharma’s infringement claim?
A: The patent covers specific sustained-release pharmaceutical formulations.
Q3: What defenses is Novartis likely to use?
A: Patent invalidity based on prior art, non-infringement, or unenforceability.
Q4: What is the significance of the claim construction order?
A: It clarifies the scope of the patent claims, critically impacting infringement and validity analyses.
Q5: How does this case compare to typical pharma patent litigations?
A: It follows common patterns of claim construction disputes, validity challenges, and motions for summary judgment.
References
- United States Patent and Trademark Office. (2017). Patent No. 9,695,663.
- District of New Jersey. (2019). Case docket 2:19-cv-00276.
- Hatch-Waxman Act. (1984). Pub. L. No. 98-417.
- Sun Pharma vs. Novartis. (2023). Official court filings.
- Patent litigations in the pharmaceutical industry: Trends and analysis. (2023). Bloomberg Law.
